Dermapharm Confirms 2022 Revenue and EBITDA Outlook at Annual General Meeting

(PLX AI) – Dermapharm board of Management confirmed the outlook for the full year, which forecast an increase of 10–13% in consolidated revenue and of 3–7% in consolidated EBITDA.Co. reports Board of Management and Supervisory Board actions were …